Last 12 months
Inside the activity.
0 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 11, 2021 Filed Aug 13, 2021 20:03 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 921 | $0.00 Strike: $108.49 | $0.00 |
DisclosureSEC source: 0000914190-21-000260 · edgar.xml · derivative · entry 4 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,942 Underlying: Common Stock · 921 shares Expires 2022-08-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:03 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 921 | $108.49 | $99,919.29 |
DisclosureSEC source: 0000914190-21-000260 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,114 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 12 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Fully exercisable. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 300 | $484.98 | $145,493.76 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 11 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,855 F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $484.64 to $485.4475, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 300 | $483.62 | $145,085.01 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 10 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,155 F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $483.59 to $483.67, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 300 | $481.61 | $144,481.50 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 9 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,455 F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $481.49 to $481.80, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 700 | $480.66 | $336,462.49 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 8 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,755 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.23 to $481.185, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 100 | $480.70 | $48,070.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 7 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,455 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $480.70 to $480.70, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,300 | $479.96 | $623,953.72 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 6 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,555 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $479.69 to $480.275, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,800 | $478.58 | $861,444.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 5 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,855 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $478.25 to $479.12, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 5,200 | $477.69 | $2,484,001.52 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 4 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,655 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $477.20 to $478.13, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 09, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 10,000 | $106.59 | $1,065,900.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 3 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionRestricted Stock Units · Derivative | 1,691 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · derivative · entry 5 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F4 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Tax withholdingCommon Stock | 869 | $481.82 | $418,701.58 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · nonDerivative · entry 2 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 822 Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC |
Kelderman KimPres. Diagnostics & Genom
|
Exercise / conversionCommon Stock | 1,691 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · nonDerivative · entry 1 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 3,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 15 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,383 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F11 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F11 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
Tax withholdingCommon Stock | 1,665 | $481.82 | $802,230.30 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 2 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,855 Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionCommon Stock | 3,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · nonDerivative · entry 1 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:20 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 1,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · derivative · entry 7 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,374 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F3 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:20 UTC |
Furlow Brenda S.SVP - General Counsel
|
Tax withholdingCommon Stock | 677 | $481.82 | $326,192.14 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · nonDerivative · entry 2 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,821 Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:20 UTC |
Furlow Brenda S.SVP - General Counsel
|
Exercise / conversionCommon Stock | 1,374 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · nonDerivative · entry 1 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:19 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionRestricted Stock Units · Derivative | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · derivative · entry 5 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,537 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F3 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:19 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Tax withholdingCommon Stock | 999 | $481.82 | $481,338.18 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · nonDerivative · entry 2 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,856 Read SEC document |
| August 08, 2021 Filed Aug 10, 2021 22:19 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
Exercise / conversionCommon Stock | 2,537 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · nonDerivative · entry 1 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 6,486 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · derivative · entry 18 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,486 Underlying: Common Stock · 6,486 shares Expires 2028-08-06 F13 · derivative.exercise_date: Options to purchase 1,622 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 1,621 shares vest on each of 8/6/2024 and 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantStock Options (Right to Buy) · Derivative | 4,864 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · derivative · entry 17 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,864 Underlying: Common Stock · 4,864 shares Expires 2028-08-06 F12 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC |
Kelderman KimPres. Diagnostics & Genom
|
GrantRestricted Stock Units · Derivative | 1,245 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000215 · edgar.xml · derivative · entry 16 Kelderman Kim · CIK 0001739054 · Pres. Diagnostics & Genom 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,245 Underlying: Common Stock · 1,245 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F12 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 20,876 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · derivative · entry 25 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,876 Underlying: Common Stock · 20,876 shares Expires 2028-08-06 F13 · derivative.exercise_date: Options to purchase 5,219 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantStock Options (Right to Buy) · Derivative | 31,315 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · derivative · entry 24 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,315 Underlying: Common Stock · 31,315 shares Expires 2028-08-06 F12 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 8,016 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · derivative · entry 23 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,016 Underlying: Common Stock · 8,016 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F12 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F12 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 16,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · derivative · entry 12 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,918 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F4 · derivative.exercise_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. F4 · derivative.expiration_date: Vested in full on 8/8/2021 upon the certification of achievement of performance goals. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Tax withholdingCommon Stock | 12,475 | $481.82 | $6,010,704.50 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · nonDerivative · entry 3 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,193 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
Exercise / conversionCommon Stock | 16,918 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · nonDerivative · entry 2 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:22 UTC |
Kummeth Charles R.Director · Chief Executive Officer
|
GrantCommon Stock | 5,344 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000217 · edgar.xml · nonDerivative · entry 1 Kummeth Charles R. · CIK 0001534980 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,750 F1 · balance_after: Includes (i) 3,763 shares of restricted stock for which the risk of forfeiture will lapse on August 7, 2022; (ii) 5,724 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2022 and August 5, 2023; and (iii) 5,344 shares of restricted stock for which the risk of forfeiture will lapse as to 1,782 shares on August 6, 2022 and as to 1,781 shares on each of August 6, 2023 and August 6, 2024. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 10,134 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 28 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,134 Underlying: Common Stock · 10,134 shares Expires 2028-08-06 F20 · derivative.exercise_date: Options to purchase 2,534 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 2,533 shares vest on each of 8/6/2024 and 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
GrantStock Options (Right to Buy) · Derivative | 7,600 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 27 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,600 Underlying: Common Stock · 7,600 shares Expires 2028-08-06 F19 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:21 UTC |
Hippel JamesChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 1,945 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000216 · edgar.xml · derivative · entry 26 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,945 Underlying: Common Stock · 1,945 shares Expires not disclosed F9 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock. F19 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F19 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:20 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 6,080 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · derivative · entry 21 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,080 Underlying: Common Stock · 6,080 shares Expires 2028-08-06 F12 · derivative.exercise_date: Options to purchase 1,520 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:20 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantStock Options (Right to Buy) · Derivative | 4,560 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · derivative · entry 20 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,560 Underlying: Common Stock · 4,560 shares Expires 2028-08-06 F11 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:20 UTC |
Furlow Brenda S.SVP - General Counsel
|
GrantRestricted Stock Units · Derivative | 1,167 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000214 · edgar.xml · derivative · entry 19 Furlow Brenda S. · CIK 0001443851 · SVP - General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167 Underlying: Common Stock · 1,167 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F11 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
GrantStock Options (Right to Buy) · Derivative | 8,107 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · derivative · entry 18 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,107 Underlying: Common Stock · 8,107 shares Expires 2028-08-06 F12 · derivative.exercise_date: Options to purchase 2,027 shares vest on each of 8/6/2022, 8/6/2023 and 8/6/2024 and options to purchase 2,026 shares vest on 8/6/2025. Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
GrantStock Options (Right to Buy) · Derivative | 6,080 | $0.00 Strike: $481.82 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · derivative · entry 17 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,080 Underlying: Common Stock · 6,080 shares Expires 2028-08-06 F11 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 06, 2021 Filed Aug 10, 2021 22:19 UTC |
Eansor Norman DavidPresident-Protein Sciences
|
GrantRestricted Stock Units · Derivative | 1,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-21-000213 · edgar.xml · derivative · entry 16 Eansor Norman David · CIK 0001270905 · President-Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,556 Underlying: Common Stock · 1,556 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F11 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $106.59 | $0.00 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · derivative · entry 15 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2023-08-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: Fully exercisable. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 100 | $466.44 | $46,644.00 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 14 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,137 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 100 | $463.56 | $46,356.00 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 13 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,237 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 300 | $462.08 | $138,625.29 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 12 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,337 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $461.71 to $462.60, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 600 | $460.71 | $276,427.98 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 11 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,637 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $460.39 to $461.25, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 800 | $459.64 | $367,711.84 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 10 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,237 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $459.34 to $460.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 12, 2021 Filed Jul 14, 2021 20:57 UTC |
Hippel JamesChief Financial Officer
|
SaleCommon Stock | 1,863 | $458.81 | $854,770.48 |
DisclosureSEC source: 0000914190-21-000195 · edgar.xml · nonDerivative · entry 9 Hippel James · CIK 0001603594 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,037 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 9, 2021. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $458.29 to $459.26, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.